These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34785763)

  • 1. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
    Sliheet E; Robinson M; Morand S; Choucair K; Willoughby D; Stanbery L; Aaron P; Bognar E; Nemunaitis J
    Cancer Gene Ther; 2022 Jul; 29(7):993-1000. PubMed ID: 34785763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
    Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Jun; 161(3):676-680. PubMed ID: 33715892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
    Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
    Rocconi RP; Stanbery L; Tang M; Madeira da Silva L; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J
    Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.
    Rocconi RP; Stevens EE; Bottsford-Miller JN; Ghamande SA; Elder J; DeMars LL; Munkarah A; Aaron P; Stanbery L; Wallraven G; Bognar E; Manley M; Horvath S; Manning L; Walter A; Galanis E; Herzog T; Monk BJ; Coleman RL; Nemunaitis J
    Cancer Gene Ther; 2022 Mar; 29(3-4):369-382. PubMed ID: 33753870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Oh J; Barve M; Matthews CM; Koon EC; Heffernan TP; Fine B; Grosen E; Bergman MK; Fleming EL; DeMars LR; West L; Spitz DL; Goodman H; Hancock KC; Wallraven G; Kumar P; Bognar E; Manning L; Pappen BO; Adams N; Senzer N; Nemunaitis J
    Gynecol Oncol; 2016 Dec; 143(3):504-510. PubMed ID: 27678295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
    Barve M; Aaron P; Manning L; Bognar E; Wallraven G; Horvath S; Stanbery L; Nemunaitis J
    Clin Med Insights Oncol; 2022; 16():11795549221110501. PubMed ID: 35957960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response.
    Nemunaitis J; Stanbery L; Willoughby D; Bognar E; Brun S; Walter A; Monk BJ; Rocconi RP; Choucair K; Coleman RL
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
    Front Oncol; 2022; 12():945867. PubMed ID: 36338747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 13. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
    Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
    Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.
    Nemunaitis J; Stanbery L; Walter A; Wallraven G; Nemunaitis A; Horvath S; Bognar E; Rao D; Engle S; Brun S; Ghisoli M; Rocconi RP; Monk BJ; Coleman RL
    Future Oncol; 2024; 20(29):2149-2164. PubMed ID: 39101448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
    Koole SN; Schouten PC; Hauke J; Kluin RJC; Nederlof P; Richters LK; Krebsbach G; Sikorska K; Alkemade M; Opdam M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; Mom CH; Arts HJG; van Ham M; van Dam P; Vuylsteke P; Sanders J; Horlings HM; van de Vijver KK; Hahnen E; van Driel WJ; Schmutzler R; Sonke GS; Linn SC
    Int J Cancer; 2022 Oct; 151(8):1394-1404. PubMed ID: 35583992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
    Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
    J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.